Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
13.83
-0.09 (-0.65%)
At close: Mar 18, 2026, 4:00 PM EDT
13.86
+0.03 (0.22%)
After-hours: Mar 18, 2026, 4:12 PM EDT
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $19.99M in the quarter ending September 30, 2025, with 18.51% growth. This brings the company's revenue in the last twelve months to $80.33M, up 27.12% year-over-year. In the year 2024, Theravance Biopharma had annual revenue of $64.38M with 12.12% growth.
Revenue (ttm)
$80.33M
Revenue Growth
+27.12%
P/S Ratio
8.72
Revenue / Employee
$828,113
Employees
97
Market Cap
700.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
| Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
| Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
| Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
| Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
| Dec 31, 2019 | 73.41M | 13.04M | 21.61% |
| Dec 31, 2018 | 60.37M | 44.98M | 292.37% |
| Dec 31, 2017 | 15.39M | -33.26M | -68.37% |
| Dec 31, 2016 | 48.65M | 6.52M | 15.48% |
| Dec 31, 2015 | 42.13M | 30.44M | 260.42% |
| Dec 31, 2014 | 11.69M | 11.46M | 5,071.68% |
| Dec 31, 2013 | 226.00K | -129.92M | -99.83% |
| Dec 31, 2012 | 130.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTBPH News
- 15 days ago - Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
- 15 days ago - Theravance plans strategic review, including possible sale, after drug trial failure - Reuters
- 15 days ago - Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript - Seeking Alpha
- 4 months ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire
- 4 months ago - Theravance Biopharma to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 months ago - Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire